AR080596A1 - Compuestos alquilamido y composiciones farmaceuticas - Google Patents

Compuestos alquilamido y composiciones farmaceuticas

Info

Publication number
AR080596A1
AR080596A1 ARP100100447A ARP100100447A AR080596A1 AR 080596 A1 AR080596 A1 AR 080596A1 AR P100100447 A ARP100100447 A AR P100100447A AR P100100447 A ARP100100447 A AR P100100447A AR 080596 A1 AR080596 A1 AR 080596A1
Authority
AR
Argentina
Prior art keywords
alkyl
hydrogen
group
rental
compounds
Prior art date
Application number
ARP100100447A
Other languages
English (en)
Inventor
Sergio Baroni
Francesca Viti
Salvatore Bellinvia
Original Assignee
Giuliani International Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Giuliani International Inc filed Critical Giuliani International Inc
Publication of AR080596A1 publication Critical patent/AR080596A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/42—Amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/008—Preparations for oily skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/06—Preparations for care of the skin for countering cellulitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00—Preparations for care of the hair
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q7/00—Preparations for affecting hair growth
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q7/00—Preparations for affecting hair growth
    • A61Q7/02—Preparations for inhibiting or slowing hair growth
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C07C233/53—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
    • C07C233/54—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of a saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/32—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C07C235/38—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/04—1,3-Dioxanes; Hydrogenated 1,3-dioxanes
    • C07D319/08—1,3-Dioxanes; Hydrogenated 1,3-dioxanes condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/74—Biological properties of particular ingredients
    • A61K2800/78—Enzyme modulators, e.g. Enzyme agonists

Abstract

Reivindicacion 1: Un compuesto de formula (1) en donde X es alquileno C1-3, opcionalmente sustituido con uno, dos o tres sustituyentes seleccionados de halogeno o hidroxilo; R1 se selecciona del grupo que consiste en alquilo C1-6, cicloalquilo C3-5, alquenilo C3-6, y alquinilo C2-6; R2 se selecciona del grupo que consiste en hidrogeno y alquilo C1-6; R3 se selecciona de modo independiente, para cada aparicion del grupo que consiste en hidrogeno, alcoxi C1-6, alquilo C1-6, ciano, cicloalquilo C3-6, halogeno, hidroxilo, y nitro; R4 se selecciona del grupo que consiste en hidrogeno y alquilo C1-6; R5 es hidrogeno, alquilo C1-6; o sus sales o N-oxidos farmacéuticamente aceptables. Reivindicacion 11: Una composicion farmacéutica que comprende un compuesto, o una de sus sales o N-oxidos farmacéuticamente aceptables, de acuerdo con cualquiera de las reivindicaciones 1-10 y un portador farmacéuticamente aceptable.
ARP100100447A 2009-02-16 2010-02-16 Compuestos alquilamido y composiciones farmaceuticas AR080596A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09425056 2009-02-16
US17906209P 2009-05-18 2009-05-18
US28746109P 2009-12-17 2009-12-17

Publications (1)

Publication Number Publication Date
AR080596A1 true AR080596A1 (es) 2012-04-25

Family

ID=42562114

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP100100447A AR080596A1 (es) 2009-02-16 2010-02-16 Compuestos alquilamido y composiciones farmaceuticas

Country Status (25)

Country Link
US (11) US8754127B2 (es)
EP (4) EP2396081B1 (es)
JP (4) JP5715070B2 (es)
KR (2) KR101800901B1 (es)
CN (3) CN104666288B (es)
AR (1) AR080596A1 (es)
AU (2) AU2010213095B2 (es)
BR (2) BRPI1011226B1 (es)
CA (2) CA2752626C (es)
CY (2) CY1119225T1 (es)
DK (2) DK2805746T3 (es)
EA (2) EA020856B1 (es)
ES (3) ES2630044T3 (es)
HR (2) HRP20170936T1 (es)
HU (2) HUE050267T2 (es)
IL (2) IL214664A (es)
LT (2) LT2396081T (es)
MX (2) MX2011008601A (es)
NZ (2) NZ595076A (es)
PL (1) PL2396081T3 (es)
PT (3) PT2805746T (es)
SI (2) SI2396081T1 (es)
UA (2) UA105037C2 (es)
WO (2) WO2010091894A2 (es)
ZA (1) ZA201106256B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITRM20050389A1 (it) 2005-07-22 2007-01-23 Giuliani Spa Composti e loro sali specifici per i recettori ppar ed i recettori per l'egf e loro uso in campo medico.
ITRM20050390A1 (it) 2005-07-22 2007-01-23 Giuliani Spa Composti e loro sali specifici per i recettori ppar ed i recettori per l'egf e loro uso in campo medico.
UA107562C2 (uk) 2008-12-05 2015-01-26 Спосіб лікування псоріазу
JP5715070B2 (ja) 2009-02-16 2015-05-07 ノグラ ファーマ リミテッド アルキルアミド化合物およびその使用
JP2014511393A (ja) * 2011-03-07 2014-05-15 セルジーン コーポレイション イソインドリン化合物を用いた疾患の治療方法
US9682923B2 (en) * 2012-02-09 2017-06-20 Nogra Pharma Limited Methods of treating fibrosis
CN104284655B (zh) 2012-04-18 2017-10-27 诺格拉制药有限公司 治疗乳糖不耐受的方法
EA201590551A1 (ru) * 2012-09-13 2015-06-30 Ногра Фарма Лимитед Способы ингибирования роста волос
PL2895160T3 (pl) * 2012-09-13 2018-09-28 Nogra Pharma Limited Sposoby leczenia stanów związanych z włosami
KR101441278B1 (ko) * 2013-11-17 2014-09-17 한규나 머리카락 분말을 이용한 재활용 방법
JP6371520B2 (ja) * 2013-12-26 2018-08-08 日本メナード化粧品株式会社 皮脂合成促進剤
AU2016246688B2 (en) 2015-04-06 2020-11-12 The Trustees Of The University Of Pennsylvania Compositions and methods for decreasing, or preventing or reversing gain of, skin pigmentation in a mammalian subject
WO2017210600A1 (en) * 2016-06-03 2017-12-07 The Scripps Research Institute Compositions and methods of modulating immune response
EP3914227A1 (en) * 2019-01-25 2021-12-01 Nogra Pharma Limited Compositions for use in preventing acne
KR20210125047A (ko) * 2019-02-08 2021-10-15 노그라 파마 리미티드 3-(4'-아미노페닐)-2-메톡시프로피온산, 및 그의 유사체 및 중간체의 제조 방법
JP6925072B1 (ja) * 2020-12-07 2021-08-25 株式会社Ｄｒ．Ｃｈｅｒｒｙ 毛髪改善のための組成物

Family Cites Families (110)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB767788A (en) 1953-12-28 1957-02-06 Schering Corp Polyiodinated phenyl fatty acid compounds and process for their manufacture
US3211610A (en) 1961-09-29 1965-10-12 Merck & Co Inc Benzoic acid ester derivatives for treating coccidiosis and method of using same
US3444232A (en) 1966-05-18 1969-05-13 Squibb & Sons Inc O-alkyl or phenylalkyl benzohydroxamic acids
GB1359560A (en) 1972-02-25 1974-07-10 Merck & Co Inc Preparation of pyrrylsalicylic acid
US4036951A (en) 1973-03-12 1977-07-19 Synergistics, Inc. Ultra-violet filtration with certain aminosalicylic acid esters
FR2440353A1 (fr) 1978-11-03 1980-05-30 Science Union & Cie Nouveaux arylethanols, leurs procedes d'obtention et leur emploi comme medicament
US4348223A (en) 1980-12-05 1982-09-07 Ppg Industries, Inc. N-Alkyl-N-[3-(alkoxyalkyl)phenyl]-2-haloacetamide herbicides
EP0055689B1 (de) 1980-12-22 1984-07-04 Schering Aktiengesellschaft In 3-Stellung substituierte 2,4,6-trihalogenierte Benzamide und deren Salze, deren Herstellung und Verwendung als Ersatzstoffe für natürliche Süssstoffe sowie Süssungsmittel auf Basis dieser Verbindungen
JPS58194814A (ja) 1982-05-11 1983-11-12 Nippon Shinyaku Co Ltd 免疫調節作用を有する薬剤
IL69282A (en) 1982-09-02 1988-06-30 Euro Celtique Sa Method for the carboxylation of potassium phenoxide with carbon dioxide
GB8302708D0 (en) 1983-02-01 1983-03-02 Efamol Ltd Pharmaceutical and dietary composition
DE3786452T2 (de) 1987-02-05 1993-10-21 Kureha Chemical Ind Co Ltd Benzylether-Verbindungen und Verfahren zu ihrer Herstellung.
US4933330A (en) 1987-04-01 1990-06-12 Dak-Laboratoriet Benzoic acid derivatives and use thereof
DE68919009T2 (de) 1988-05-05 1995-02-23 Tillotts Pharma Ag Verwendung von 5-Amino-salicylsäure für die Behandlung von Hautkrankheiten.
US5519014A (en) 1990-10-22 1996-05-21 Borody; Thomas J. Treatment of non-inflammatory and non-infectious bowel disorders
CA2090220C (en) 1990-10-22 2003-07-08 Thomas Julius Borody Treatment of non-inflammatory and non-infectious bowel disorders
US5262549A (en) 1991-05-30 1993-11-16 Polaroid Corporation Benzpyrylium dyes, and processes for their preparation and use
US5302751A (en) 1992-01-21 1994-04-12 Ethyl Corporation Profen resolution
CA2132199C (en) 1992-03-17 2000-01-18 Hitoshi Nishiyama Depsipeptide derivative, production thereof and use thereof
AU674330B2 (en) 1992-06-30 1996-12-19 Howard K. Shapiro Composition containing amine and amine-related derivatives of benzoic acid and uses therefor including treating inflammatory diseases
US5594151A (en) 1994-01-28 1997-01-14 Prolinx, Inc. Phenylboronic acid complexing reagents derived from aminosalicylic acid
WO1995031194A1 (en) 1994-05-11 1995-11-23 Shapiro Howard K Compositions for treatment of chronic inflammatory diseases
US5594015A (en) 1994-06-22 1997-01-14 Regents Of The University Of California Thiazolidine derivatives for the treatment of psoriasis
EP0817631A2 (en) 1995-03-28 1998-01-14 Janssen Pharmaceutica N.V. Low dose ridogrel formulations and their use for the treatment of inflammatory bowel diseases
GB9600464D0 (en) 1996-01-09 1996-03-13 Smithkline Beecham Plc Novel method
GB9617001D0 (en) 1996-08-13 1996-09-25 Tillotts Pharma Ag Oral composition
DE19647582A1 (de) 1996-11-18 1998-05-20 Hoechst Ag Verfahren zur Herstellung von aromatischen Olefinen mittels Katalyse durch Palladaphosphacyclobutane
AU6773598A (en) 1997-03-26 1998-10-20 Institut Pasteur Treatment of gastrointestinal disease with ppar modulators
US7098025B1 (en) 1997-07-25 2006-08-29 Ligand Pharmaceuticals Incorporated Human peroxisome proliferator activated receptor gamma (pparγ) gene regulatory sequences and uses therefor
WO1999015520A1 (fr) 1997-09-19 1999-04-01 Ono Pharmaceutical Co., Ltd. Composes de benzene fusionnes ou non fusionnes
US7015249B1 (en) 1997-12-12 2006-03-21 Purdue Research Foundation Methods and compositions for treating diabetes
FR2773075B1 (fr) 1997-12-31 2000-05-05 Cird Galderma Utilisation d'activateurs de ppar-gamma en dermatologie
US6114382A (en) 1998-11-11 2000-09-05 Moretti; Itagiba G. Methods for treating inflammatory bowel disease
US6326364B1 (en) 1999-02-08 2001-12-04 Cedars-Sinai Medical Center Use of 5-aminosalicylates as antimicrobial agents
FR2791671B1 (fr) 1999-04-01 2001-05-11 Oreal Nouveaux composes derives d'esters d'acide benzoique, composition les comprenant et utilisation
GB9908647D0 (en) 1999-04-15 1999-06-09 Smithkline Beecham Plc Novel compounds
US20040034067A1 (en) 1999-04-15 2004-02-19 Macphee Colin Houston Novel method of treatment
GB9914371D0 (en) 1999-06-18 1999-08-18 Smithkline Beecham Plc Novel compounds
TWI262185B (en) * 1999-10-01 2006-09-21 Eisai Co Ltd Carboxylic acid derivatives having anti-hyperglycemia and anti-hyperlipemia action, and pharmaceutical composition containing the derivatives
US6369098B1 (en) 1999-10-05 2002-04-09 Bethesda Pharmaceuticals, Inc. Dithiolane derivatives
US7736661B1 (en) 2000-03-07 2010-06-15 Avon Products, Inc Method of treating skin conditions
ATE275127T1 (de) 2000-04-19 2004-09-15 Neurotech Co Ltd Verbindungen, zusammensetzungen und verfahren zur vorbeugung der neurodegeneration bei akuten oder chronischen verletzungen des zentralen nervensystems
AU2001258838A1 (en) * 2000-05-29 2001-12-11 Kyorin Pharmaceutical Co. Ltd. Substituted phenylpropionic acid derivatives
US7049342B2 (en) 2000-05-29 2006-05-23 Kyorin Pharmaceutical Co., Ltd. Substituted phenylpropionic acid derivatives
ATE448194T1 (de) 2000-08-29 2009-11-15 Biocon Ltd Verwendung einer pharmazeutischen zusammensetzung mit einem para-aminophenylessigsäurederivat für die behandlung von entzündlichen erkrankungen des magen-darmtrakts
EP1348698A4 (en) * 2000-12-05 2005-01-19 Kyorin Seiyaku Kk SUBSTITUTED CARBOXYLENE DERIVATIVES
US7312247B2 (en) 2001-03-27 2007-12-25 Errant Gene Therapeutics, Llc Histone deacetylase inhibitors
FR2822955B1 (fr) 2001-03-27 2003-10-03 Chru Lille Methode de diagnostic de maladies inflammatoires chroniques de l'intestin
CA2443935A1 (en) 2001-04-18 2002-10-31 Merck & Co., Inc. Ppar-alpha-gamma ligands or agonists for the treatment of inflammation
CA2354921A1 (en) 2001-05-24 2002-11-24 Yasuo Konishi Drug evolution: drug design at hot spots
PL369732A1 (en) 2001-10-16 2005-05-02 Dr.Reddy's Laboratories Ltd. Benzoxazine and benzothiazine derivatives and pharmaceutical compositions containing them
WO2003043569A2 (en) 2001-11-16 2003-05-30 Nutrition 21, Inc. Trans-10, cis-12 conjugated linoleic acid isomer for the treatment of diseases
GB0127916D0 (en) 2001-11-21 2002-01-16 Rowett Res Inst Method
WO2003045383A1 (en) 2001-11-26 2003-06-05 Arachnova Therapeutics Ltd. Use of ppar activators for the treatment of pulmonary fibrosis
UA82835C2 (en) * 2001-12-03 2008-05-26 Reddys Lab Ltd Dr ?-aryl-?-oxysubstituted propionuc acid derivatives and pharmaceutical composition based thereon
US20030113815A1 (en) 2001-12-19 2003-06-19 Pfizer Inc. Canine peroxisome proliferator activated receptor gamma
WO2003053974A1 (en) 2001-12-21 2003-07-03 Dr. Reddy's Laboratories Ltd. Novel compounds and their use in medicine, process for their preparation and pharmaceutical compositions containing them
US20030220374A1 (en) 2002-01-14 2003-11-27 Pharmacia Corporation Compositions and methods of treatment involving peroxisome proliferator-activated receptor-gamma agonists and cyclooxygenase-2 selective inhibitors
US20040115127A1 (en) 2002-04-12 2004-06-17 Wright Samuel D. Ppar-alpha-gamma ligands or agonists for the treatment of inflammation
US8492438B2 (en) 2002-04-26 2013-07-23 Asan Laboratories Company (Cayman), Limited Treatment skin disorders
AU2003228744A1 (en) 2002-04-29 2003-11-17 The Ohio State University Inhibition of protein tyrosine phosphatases and sh2 domains by a neutral phosphotyrosine mimetic
DE10250080A1 (de) 2002-10-25 2004-05-13 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
GB0303609D0 (en) 2003-02-17 2003-03-19 Glaxo Group Ltd Novel therapeutic method and compositions
US20060159648A1 (en) 2003-02-17 2006-07-20 Davis Adrian F Novel therapeutic method and compositions for topical administration
EP1607103A1 (en) 2003-03-20 2005-12-21 Eisai Co., Ltd. Concomitant drug as therapeutic agent for inflammatory bowel disease
ATE455772T1 (de) 2003-07-21 2010-02-15 Merck Serono Sa Alkinylarylcarbonsäureamide
UA60954C2 (en) 2003-07-25 2006-03-15 Subsidiary Entpr With Foreign Method for measuring conductivity of electrolyte by a contactless measuring transducer
JP2007509180A (ja) 2003-10-21 2007-04-12 インスパイアー ファーマシューティカルズ，インコーポレイティド 疼痛を治療するための、非ヌクレオチド組成物および方法
US20070093476A1 (en) 2003-10-28 2007-04-26 Bhunia Debnath Novel compounds and their use in medicine,as antidiabetic and hypolipidemic agents, process for their preparation and pharmaceutical compositions containing them
FR2862870A1 (fr) 2003-12-01 2005-06-03 Galderma Res & Dev Utilisation d'activateurs de recepteurs ppar en cosmetique et dermatologie.
EP1691806A2 (en) 2003-12-03 2006-08-23 Smithkline Beecham Corporation Novel therapeutic method and compositions
EP1722630A4 (en) 2004-01-20 2009-05-27 Richard F Harty COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY DISEASES
WO2005084658A1 (en) * 2004-03-04 2005-09-15 Arakis Ltd. Derivatives of actarit and their therapeutic use
US20050277693A1 (en) 2004-06-10 2005-12-15 Dr. Reddy's Laboratories Limited Basic salts and monohydrates of certain alpha, beta-propionic acid derivative
PE20060594A1 (es) 2004-09-09 2006-08-18 Novartis Ag Composicion farmaceutica que contiene un agonista de ppar
CA2581930A1 (en) 2004-09-27 2006-04-06 Jane Trepel Modulating mxa expression
US20060286046A1 (en) 2005-01-05 2006-12-21 Haber C Andrew Skin care compositions
EP1719543A1 (en) 2005-05-04 2006-11-08 Asan Labs., Ltd. Use of histone deacetylase inhibitors for the treatment of gastrointestinal distress
US20060270635A1 (en) 2005-05-27 2006-11-30 Wallace John L Derivatives of 4- or 5-aminosalicylic acid
ITRM20050389A1 (it) 2005-07-22 2007-01-23 Giuliani Spa Composti e loro sali specifici per i recettori ppar ed i recettori per l'egf e loro uso in campo medico.
ITRM20050390A1 (it) 2005-07-22 2007-01-23 Giuliani Spa Composti e loro sali specifici per i recettori ppar ed i recettori per l'egf e loro uso in campo medico.
DE102005061472A1 (de) 2005-12-22 2007-07-05 Saltigo Gmbh Verfahren zur Herstellung von enantiomerenangereicherten 2-Alkoxy-3-phenylpropionsäuren
WO2007096148A1 (en) 2006-02-23 2007-08-30 Lipid Nutrition B.V. Immunoregulation
US7645801B2 (en) 2007-01-29 2010-01-12 Alaven Pharmaceutical Llc Reduced irritant enema for treatment of inflammatory bowel disease (IBD)
IE20070129A1 (en) 2007-02-28 2008-12-24 Giuliani Int Ltd Ppar-gamma agonists stimulate enteric defensin expression
US8796282B2 (en) 2007-03-28 2014-08-05 Case Western Reserve University Method of treating dermatological disorders
US20090054312A1 (en) 2007-08-22 2009-02-26 Wolf Dieter A SMIPs: Small molecule inhibitors of p27 depletion in cancers and other proliferative diseases
ITMI20072429A1 (it) 2007-12-24 2009-06-25 Giuliani Int Ltd Composti per il trattamento selettivo della componente immuno-infiammatoria intestinale della malattia celiaca
US8030520B2 (en) 2008-03-31 2011-10-04 Saltigo Gmbh Process for preparing organic compounds by a transition metal-catalysed cross-coupling reaction of an aryl-X, heteroaryl-X, cycloalkenyl-X or alkenyl-X compound with an alkyl, alkenyl, cycloalkyl or cycloalkenyl halide
UA107562C2 (uk) 2008-12-05 2015-01-26 Спосіб лікування псоріазу
JP5715070B2 (ja) 2009-02-16 2015-05-07 ノグラ ファーマ リミテッド アルキルアミド化合物およびその使用
EP2298321A1 (en) 2009-08-26 2011-03-23 Nordic Pharma Novel pharmaceutical compositions for treating IBD
WO2013012662A2 (en) 2011-07-15 2013-01-24 S.L.A. Pharma Ag Pharmaceutical compositions for rectal administration
EP2775839B1 (en) 2011-10-17 2023-12-06 The Regents of The University of California Methods for assessing repellant quality of organic materials and methods and compositions for repelling arthropods
WO2013064153A1 (en) 2011-10-31 2013-05-10 Claus Selch Larsen Prodrugs of non- steroid anti - inflammatory agents (nsaids)
US9682923B2 (en) 2012-02-09 2017-06-20 Nogra Pharma Limited Methods of treating fibrosis
CN104284655B (zh) 2012-04-18 2017-10-27 诺格拉制药有限公司 治疗乳糖不耐受的方法
JP6096179B2 (ja) 2012-05-10 2017-03-15 国立大学法人岩手大学 ラクターゼ活性を有するタンパク質、該タンパク質をコードする遺伝子、該遺伝子を含有する組み換えベクター、形質転換体、及びその製造方法並びに用途
US9013997B2 (en) 2012-06-01 2015-04-21 Broadcom Corporation System for performing distributed data cut-through
JP2015521195A (ja) 2012-06-01 2015-07-27 ノグラ ファーマ リミテッド Ｔ細胞受容体を調節することができる二環式複素環およびそれを使用するための方法
CA2875964C (en) 2012-06-07 2018-01-02 Georgia State University Research Foundation, Inc. Seca inhibitors and methods of making and using thereof
PL2895160T3 (pl) 2012-09-13 2018-09-28 Nogra Pharma Limited Sposoby leczenia stanów związanych z włosami
EA201590551A1 (ru) 2012-09-13 2015-06-30 Ногра Фарма Лимитед Способы ингибирования роста волос
CN105377247B (zh) 2013-03-26 2019-04-26 脂质治疗有限公司 用于治疗溃疡性结肠炎含磷脂酰胆碱的药物制剂
CN105566153B (zh) 2014-10-14 2019-05-31 中国医学科学院药物研究所 偶氮苯衍生物及其制法和药物组合物与用途
WO2016154730A1 (en) 2015-04-02 2016-10-06 University Health Network Gut anti-inflammatory agents for regulation of high blood glucose levels
EP3307262B1 (en) 2015-06-15 2021-05-19 NMD Pharma A/S Compounds for use in treating neuromuscular disorders
WO2017046343A1 (en) 2015-09-17 2017-03-23 Nogra Pharma Limited Compositions for rectal administration in the treatment of ulcerative colitis and methods of using same
WO2017093444A1 (en) 2015-12-01 2017-06-08 Nogra Pharma Limited Compositions for oral administration in the treatment of inflammatory bowel disease
WO2017144725A1 (en) 2016-02-26 2017-08-31 Nogra Pharma Limited Methods of treating lactose intolerance

Also Published As

Publication number Publication date
IL214665A (en) 2017-02-28
US20150148418A1 (en) 2015-05-28
MX2011008601A (es) 2011-09-09
IL214665A0 (en) 2011-09-27
CN104666288B (zh) 2017-08-04
CN102316931A (zh) 2012-01-11
ES2429143T3 (es) 2013-11-13
DK2396081T3 (en) 2017-07-10
CA2752623C (en) 2017-07-04
JP5645851B2 (ja) 2014-12-24
US20180369178A1 (en) 2018-12-27
KR20110120945A (ko) 2011-11-04
US20150051285A1 (en) 2015-02-19
JP2012517969A (ja) 2012-08-09
BRPI1008752A2 (pt) 2016-03-08
PT2396081T (pt) 2017-07-11
CY1123213T1 (el) 2021-12-31
EA201171062A1 (ru) 2012-01-30
JP2014237692A (ja) 2014-12-18
EA020198B1 (ru) 2014-09-30
EP2396082A2 (en) 2011-12-21
JP2012517968A (ja) 2012-08-09
CN102316932A (zh) 2012-01-11
ES2806691T3 (es) 2021-02-18
NZ595076A (en) 2013-09-27
EP2396082B1 (en) 2013-07-31
HUE032999T2 (hu) 2017-11-28
US20190269637A1 (en) 2019-09-05
PT2805746T (pt) 2020-08-17
EP3744398A1 (en) 2020-12-02
KR101776337B1 (ko) 2017-09-07
NZ595080A (en) 2013-09-27
UA109525C2 (xx) 2015-09-10
AU2010213093B2 (en) 2016-01-07
AU2010213093A1 (en) 2011-09-08
US9901557B2 (en) 2018-02-27
EA201171063A1 (ru) 2012-01-30
UA105037C2 (uk) 2014-04-10
US20160338927A1 (en) 2016-11-24
HRP20201184T1 (hr) 2020-12-11
WO2010091894A3 (en) 2010-11-11
ES2630044T3 (es) 2017-08-17
WO2010091892A3 (en) 2010-10-21
US9511041B2 (en) 2016-12-06
CA2752623A1 (en) 2010-08-19
EP2805746B1 (en) 2020-05-06
KR101800901B1 (ko) 2017-11-23
PL2396081T3 (pl) 2017-10-31
AU2010213095A1 (en) 2011-09-08
SI2805746T1 (sl) 2020-10-30
WO2010091894A2 (en) 2010-08-19
LT2396081T (lt) 2017-09-11
JP2015155427A (ja) 2015-08-27
DK2805746T3 (da) 2020-08-10
BRPI1011226B1 (pt) 2019-10-29
US20220354809A1 (en) 2022-11-10
CN102316931B (zh) 2014-11-19
PT2396082E (pt) 2013-10-03
US10137101B2 (en) 2018-11-27
US8754127B2 (en) 2014-06-17
AU2010213095B2 (en) 2015-09-17
WO2010091892A2 (en) 2010-08-19
IL214664A0 (en) 2011-09-27
BRPI1011226A2 (pt) 2016-03-15
EP2805746A1 (en) 2014-11-26
SI2396081T1 (sl) 2017-09-29
US20120053244A1 (en) 2012-03-01
MX2011008602A (es) 2011-09-09
CA2752626C (en) 2018-03-27
HUE050267T2 (hu) 2020-11-30
EA020856B1 (ru) 2015-02-27
US10959970B2 (en) 2021-03-30
US20120053245A1 (en) 2012-03-01
ZA201106256B (en) 2012-05-30
US20170172956A1 (en) 2017-06-22
EP2396081A2 (en) 2011-12-21
US20200188340A1 (en) 2020-06-18
LT2805746T (lt) 2020-09-25
CN102316932B (zh) 2014-07-09
IL214664A (en) 2015-09-24
JP5715070B2 (ja) 2015-05-07
EP2396081B1 (en) 2017-04-05
KR20110120946A (ko) 2011-11-04
US8796334B2 (en) 2014-08-05
CN104666288A (zh) 2015-06-03
CY1119225T1 (el) 2018-02-14
US10398667B2 (en) 2019-09-03
JP5820030B2 (ja) 2015-11-24
CA2752626A1 (en) 2010-08-19
BRPI1008752B1 (pt) 2020-02-11
HRP20170936T1 (hr) 2017-09-22
US20200383942A1 (en) 2020-12-10

Similar Documents

Publication Publication Date Title
AR080596A1 (es) Compuestos alquilamido y composiciones farmaceuticas
AR078163A1 (es) Utilizacion de aminodihidrotiazinas para el tratamiento o prevencion de la diabetes
AR073136A1 (es) Compuestos de pirrol
AR072906A1 (es) Nucleosidos modificados utiles como antivirales
AR085615A1 (es) Derivados de fluoropiridinona utiles como agentes antibacterianos y composiciones farmaceuticas que los contienen
AR063912A1 (es) Derivados de 1,2,4 oxadiazol. composiciones farmaceuticas.
ES2530943T3 (es) Derivados de la cromenona con actividad antitumoral
PE20142456A1 (es) COMPUESTOS DE OXAZOLIDIN-2-ONA Y USOS DE LOS MISMOS COMO INHIBIDORES DE LA PI3Ks
BR112014002675A2 (pt) "quinazolina como inibidores de serina/treonina quinase, seus usos, e composição"
PE20142081A1 (es) Inhibidores de quinurenina-3-monooxigenasa, composiciones farmaceuticas y metodo de uso de los mismos
AR074021A1 (es) Compuestos heterociclicos fusionados como moduladores del canal ionico
AR062677A1 (es) Derivados de biaril-sulfonamida, procesos de produccion y composiciones farmaceuticas que los comprenden
AR079205A1 (es) Morfolinotiazoles como moduladores alostericos positivos alfa 7
AR072166A1 (es) Derivado de piperidina y su uso como inhibidor de renina superior
AR087311A1 (es) Quinolinas sustituidas y su uso como medicamentos
BR112014006660A2 (pt) novos derivados de dihidroquinolina-2-ona bicíclicos
AR091519A1 (es) Inhibidores pirrolopirazona de tanquirasa
PE20141167A1 (es) Piridopirazinas sustituidas como inhibidores novedosos de ptk
AR056025A1 (es) Compuestos de imidazol sustituidos como inhibidores de ksp
BR112014010644A2 (pt) novos derivados de aril-quinolina
PE20141380A1 (es) Imidazopiridazinas como inhibidores de quinasa akt
CU20090048A7 (es) Nuevos derivados de diosmetina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
UY29739A1 (es) Derivados de amidas o sales farmacéuticamente aceptables de los mismos, procesos de preparaciones farmacéuticas conteniéndolos y aplicaciones
AR052370A1 (es) Tiazolidinonas y su uso como inhibidores de la poloquinasa(plk)
AR077301A1 (es) Derivados de 2-carboxamida-7-piperazinil-benzofurano como antagonistas de 5-ht1a y 5-ht1b

Legal Events

Date Code Title Description
FG Grant, registration